Randomized controlled trialHumanClinical Trial, Phase III
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Nature medicine, 2026 Aug. Kaplan LM, Startseva E, le Roux CW and 12 others.
Study type
Randomized controlled trial · Clinical Trial, Phase III
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Nature medicine
Published
2026 Aug
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
HumansFemaleMaleObesityDouble-Blind MethodMiddle AgedAdultFatty LiverLiverMagnetic Resonance ImagingBody Mass Index
Other papers on Survodutide
Randomized controlled trial · 2026
Survodutide Once Weekly for the Treatment of Adults with Obesity
Randomized controlled trial · 2024Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Journal article · 2026Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page